- Taking dalcetrapib after acute coronary syndrome reduces the risk of developing type 2 diabetes2020 | Second Faculty of Medicine
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome2012 | Faculty of Medicine in Hradec Králové
- Choosing approaches to treatment of hyperlipoproteinaemia and dyslipidaemia in a patient with diabetes2014 | First Faculty of Medicine
- The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial2014 | Faculty of Medicine in Hradec Králové